{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "dLRRK",
          "alt": "I1915T",
          "position": "I1915T"
        },
        "variant_string_id": "LRRK2 dLRRK I1915T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Gain-of-function mutations in LRRK2 cause familial as well as sporadic Parkinson’s disease (PD) characterized by age-dependent dopaminergic neuron (DN) degeneration. Pathogenic LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism involving LRRK2 mutations and their role in PD through miRNA pathway deregulation."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Reporter gene assays (EGFP-let-7-3′UTR) and protein interaction assays (dAgo1, hAgo2) were used to assess miRNA function and LRRK2 effects.",
          "judgment": "Yes",
          "reasoning": "The assays used effectively model the disease mechanism by directly testing miRNA regulation and LRRK2's role in it."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Basic controls (wild-type, pathogenic mutations) and replicates were included. Known pathogenic variants (I1915T, G2019S) were tested.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were present, but variant-specific controls (known benign/pathogenic) were not explicitly mentioned."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No statistical analyses or OddsPath values were provided. Fewer than 10 controls were used.",
          "judgment": "Max PS3_supporting",
          "reasoning": "Insufficient controls and lack of statistical analysis limit the strength to supporting."
        }
      ],
      "functional_evidence_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "hLRRK2",
          "alt": "G2019S",
          "position": "G2019S"
        },
        "variant_string_id": "LRRK2 hLRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Gain-of-function mutations in LRRK2 cause familial as well as sporadic Parkinson’s disease (PD) characterized by age-dependent dopaminergic neuron (DN) degeneration. Pathogenic LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism involving LRRK2 mutations and their role in PD through miRNA pathway deregulation."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Reporter gene assays (EGFP-let-7-3′UTR) and protein interaction assays (dAgo1, hAgo2) were used to assess miRNA function and LRRK2 effects.",
          "judgment": "Yes",
          "reasoning": "The assays used effectively model the disease mechanism by directly testing miRNA regulation and LRRK2's role in it."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Basic controls (wild-type, pathogenic mutations) and replicates were included. Known pathogenic variants (I1915T, G2019S) were tested.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were present, but variant-specific controls (known benign/pathogenic) were not explicitly mentioned."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No statistical analyses or OddsPath values were provided. Fewer than 10 controls were used.",
          "judgment": "Max PS3_supporting",
          "reasoning": "Insufficient controls and lack of statistical analysis limit the strength to supporting."
        }
      ],
      "functional_evidence_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "dLRRK",
          "alt": "kinase-dead",
          "position": "3KD"
        },
        "variant_string_id": "LRRK2 dLRRK 3KD"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Gain-of-function mutations in LRRK2 cause familial as well as sporadic Parkinson’s disease (PD) characterized by age-dependent dopaminergic neuron (DN) degeneration. Pathogenic LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism involving LRRK2 mutations and their role in PD through miRNA pathway deregulation."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Reporter gene assays (EGFP-let-7-3′UTR) and protein interaction assays (dAgo1, hAgo2) were used to assess miRNA function and LRRK2 effects.",
          "judgment": "Yes",
          "reasoning": "The assays used effectively model the disease mechanism by directly testing miRNA regulation and LRRK2's role in it."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Basic controls (wild-type, pathogenic mutations) and replicates were included. Known pathogenic variants (I1915T, G2019S) were tested.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were present, but variant-specific controls (known benign/pathogenic) were not explicitly mentioned."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No statistical analyses or OddsPath values were provided. Fewer than 10 controls were used.",
          "judgment": "Max BS3_supporting",
          "reasoning": "Insufficient controls and lack of statistical analysis limit the strength to supporting."
        }
      ],
      "functional_evidence_strength": "BS3_supporting"
    }
  ]
}